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Improving anemia by hemodialysis: Effect on serum erythro-
poietin. Serum erythropoietin (SEP) concentration was measured
on two occasions in 42 patients with terminal renal failure (1)
immediately before the first hemodialysis, and (2) 3 to 27 months
following the onset of regular hemodialysis treatment. Although
the hematocrit (Hct) showed an increase in every patient, the SEP
concentration decreased in every patient. The mean Hct rose
from 21.7 to 28.6% (volume per volume) (P <0.001). and the SEP
dropped from 509 to 182 mU/mi (P < 0.001). This shows that
anemia improvement is not a consequence of increased erythro-
poietin production but that it is most likely due to elimination of
an inhibitor of the bone marrow by hemodialysis treatment. The
decrease of SEP concentration has to be interpreted as a response
to the improved tissue oxygenation that correlates with the high-
er hematocnt or as a consequence of further reduction of renal
mass with progress of the renal disease.
L'amélioration de l'anémie de t'insuffisance rénale: Effet sur
l'érythropoietine sérique. La concentration d'érythropoIétine Se-
rique (SEP) a été mesurCe chez 42 malades atteints d'insuffisance
rénale terminale, a deux reprises: (1) immédiatement avant Ia
premiere hdmodialyse et (2) 3 a 27 mois aprés le debut de
l'hCmodialyse intérative. Alors que l'hématocrite (Hct) augmen-
tait chez tous les malades, SEP diminuait. L'hématocrite moyen
est passé de 21.7 a 28,6% (P <0,001), SEP moyen a baissé de 509
a 182 mU/mi (P < 0,001). Cela montre que l'amélioration de
l'anémie n'est pas Ia consequence d'une augmentation de La pro-
duction d'érythropoIétine, mais plus probablement liée a
l'Climination par l'hémodialyse d'un inhibiteur de la moelle as-
seuse. La diminution de SEP doit être interprdtde comme Ia ré-
ponse a une meilleure oxygenation tissulaire du fait de
l'augmentation de l'hématocrite ou la consequence d'une dimi-
nution de Ia masse rCnale liée a l'évolution de l'affection.
An elevated serum erythropoietin (SEp) concen-
tration is only occassionally found in anemic pa-
tients with end-stage renal failure [1—3], and it is
generally accepted that erythropoietin deficiency
is a cause of renal anemia.
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Because peripheral hemoglobin concentrations
increase significantly in almost every patient follow-
ing the onset of regular hemodialysis treatment [1,
4, 5], and because there are sporadic reports of in-
crease of SEP that coincides with a shortening of ra-
dioactive iron-marrow transit time [1, 61, some in-
vestigators concluded that improvement of erythro-
poiesis is at least partly due to a gradual increase of
renal or extrarenal erythropoietin production that
was originally depressed by inhibitors accumulating
in uremia [1, 6-81. Others did not find the concen-
tration of SEP to be elevated after regular hemo-
dialysis treatment was begun [9-11], and Erslev re-
ported the production of erythropoietin to be unaf-
fected by uremic serum added to the perfusion fluid
of the isolated hypoxic kidneys of rabbits [12].
In the attempt to solve the controversy, we mea-
sured, by using the sensitive fetal mouse liver cell
assay, the SEP concentrations in a large group of pa-
tients with terminal renal failure before and after the
onset of regular dialysis treatment. Our purpose
was to find out if the improvement of anemia follow-
ing regular hemodialysis treatment is accompanied
by a consistent change in SEP concentration.
Methods
On two occasions, we determined the 5EP con-
centrations and the hematocrits of 42 (27 male and
15 female) nonbilateral nephrectomized patients
with end-stage renal failure. This was done (1) im-
mediately before the first dialysis treatment when
the patients were in a state of severe uremic intoxi-
cation, and (2) 3 to 27 months after the start of regu-
lar hemodialysis treatment (three 6- to 8-hr treat-
ments per week). For controls, we used 59 healthy
subjects. Dialysis was performed either with a Kiil
dialyzer or with various disposable dialyzers with
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an effective surface area of I m2 and cuprophane
membranes of 11.5 to 13.5 j. All patients were
on oral or parenteral iron substitution therapy. No
blood transfusions or androgens were given, and no
major accidental blood loss occurred during the
study.
SEP was measured with the fetal mouse liver cell
bioassay described elsewhere [13, 14] with minor
modifications [15]. Briefly, livers from 14-day-old
mouse fetuses were dissected and cells suspended
in a culture medium (Eagles Minimal Essential Me-
dium) containing 10% (volume/volume) fetal calf
serum and 5% (volume/volume) bicarbonate and
carbon dioxide buffer with test sera or erythro-
poietin standard added. After 20 hours of in-
cubation at 37° C, 1 pCi of radioactive iron pre-
viously bound to an equivalent amount of pure hu-
man transferrin (Behring Marburg) was added for
pulse labeling for another 4 hours of incubation at
37° C. Heme was chemically extracted by using hy-
drochloric acid, Drabkin's solution, and butanone,
and its radioactivity was measured in a $-liquid
scintillation counter.
In another series of experiments, the specifity of
the in vitro assay was tested. Human urinary
erythropoietin (50 and 200 mU/mI) was pre-
incubated for 3 hours with rabbit antiserum having
an estimated potency capable of neutralizing 50
mU/mi of human erythropoietin. The effect in the
fetal mouse liver cell culture was compared to a sa-
line control and to the effect of an erythropoietin
control culture (50 mU/ml) without antiserum.
To minimize the differences of the specific activi-
ty of radioactive iron transferrin due to different iron
concentrations in the various test serum samples,
we limited the test serum portion in the culture to
4% (volume/volume), we counterbalanced the vari-
ation of iron concentration in the serum samples by
the constant iron pool of the fetal calf serum, which
contained 270 g of iron per deciliter, and we added
the transferrin-bound iron in a constant amount (5
to 10 1g/dl of culture medium) for pulse labeling af-
ter 20 hours of incubation [151. Because the iron
concentrations of the test sera ranged from 38 to 142
pg/dl, causing a 10% (maximum) difference of the
specific activity of radioactive iron transferrin in the
culture medium, the resulting error of the measure-
ment was well within the limits of accuracy of the
method, with an index of precision ranging from
0.04 to 0.20 and 95% confidence limits of usually 80
to 120% of the mean potency [161. So, no individual
correction for iron concentration of the test serum
sample was made. For laboratory standard, we
used both a crude erythropoietin preparation (Con-
naught Laboratories, Toronto, Canada; step 3) and
a healthy volunteer's serum sample, which was di-
vided in 200 portions and kept deep-frozen until as-
sayed. The laboratory standards were calibrated
against the International Standard Preparation B
(courtesy of the WHO Laboratory for Biological
Standards, Mill Hill, London [17]). SEP concentra-
tions were expressed in international units (milli-
units per milliliter). To have an exact estimate of the
validity of every erythropoietin measurement, we
determined a complete log dose-response relation-
ship by assaying every serum sample in serial dilu-
tions of three to four steps of five replicates, and we
compared it to the standard samples assayed in the
same way. Accordingly, the estimation of each
serum sample was made from 15 to 20 cultures.
The two-paired serum samples of each individual
patient were always measured in the same assay, to
allow a direct comparison of the corresponding
samples. By doing this, we increased the accuracy
of the estimate. We proved the validity of every
measurement by checking the significance of re-
gression and by checking the absence of a signifi-
cant deviation from linearity and parallelism in the
log dose-response relationship of test and standard
samples simultaneously, using the analysis of vari-
ance [8, 19]. The analysis of variance and the calcu-
lation of the mean erythropoietin potency of the
serum samples and their 95% confidence limits were
performed in the computer center of the Johann
Wolfgang Goethe University at Frankfurt am Main.
We used Student's paired t test to evaluate the clini-
cal data.
Results
The 5EP concentrations and hematocrits are shown
in Fig. 1. The solid lines represent the mean values.
5EP concentrations decreased in all patients, but the
hematocrits increased. The SEP concentrations be-
fore hemodialysis varied widely and ranged from 76
to 3070 mU/mi, whereas the hematocrits before
dialysis ranged from 13 to 30% (volume/volume).
Three to twenty-seven months after onset of regular
hemodialysis treatment, 5EP concentrations ranged
from 57 to 667 mU/mi; the corresponding hemato-
crits ranged from 19 to 41%. The differences be-
tween values before and after treatment are highly
significant, when tested with the Student's com-
bined t test (P < 0.001).
Table I shows the mean SEp concentrations and
the mean hematocrits before and after dialysis treat-
ment in comparison with the mean values of the
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control group. Mean SEP concentrations on both oc-
casions were significantly higher than the mean SEP
concentrations of normal controls (509 [SD] 440
mU/ml, and 182 [SD] 110 mU/l, vs. 136 [SD] 66
mU/mi; P <0.01). At the same time, mean hemato-
crits were significantly lower than the mean control
values (21.6 [SD] 3.6%, and 28.7 [SD] 4.9% [vol-
ume/volume], vs. 42.7 [SD] 3.9%; P < 0.001).
Figure 2 shows the effect of rabbit antiserum
against human urinary erythropoietin. Fifty neutral-
izing milliunits completely blocked the iron incor-
poration generated by 50 mU of human erythro-
poietin, as compared to the saline control culture.
Table 1. Serum erythropoietin (SEP) and hematocrit before and
after 3 to 27 months of regular dialysis treatmenta
Hematocrit
SEP
in U/in!
% (vol/vol)
Normal
controlsNormal
Before After controls Before After (N = 59)
509 182 136 21,6 28.7 42.7
440 110 66 3.6 4.9 3.9
e—P <0.001 —*'-P <0.01 — -P <0.01 —a—P <0.001-*
—P<0.001--- e—P<0.00l--a
a Values are the means SD.
fin
50 50 Saline control 200 EP,rnU/mI
+ +
50 50 Anti-Ep, mU/mi
Fig. 2.Neutralizing effect of rabbit antiserum against human un-
nary ervthropoietin (EP). Complete blocking (column 2) by
equivalent amount of antiserum can be overcome by human
erythropoietin added in excess (column 4). Values are the means
SD of three cultures.
The blocking effect of the antiserum was overcome
when erythropoietin was added in excess to the cul-
ture (200 mU/mi), proving the neutralizing capabili-
ty of the antiserum to be specific and not due to a
cytotoxic influence on the cell culture.
Discussion
The serum erythropoietin (SEp) concentrations of
normal subjects reported in the literature vary wide-
ly. The range from 3.7 to 11 mU/mi when measured
with a radioimmunoassay [20] to 320 rnU/ml when
measured with the polycythemic mouse assay [11].
Large differences of SEP concentrations of nor-
mal sera are also found when identical or similar
methods are used. With the most frequently applied
bioassay (the polycythemic mouse assay), most in-
vestigators are unable to detect SEP concentrations
in normal subjects [1—3,9, 10]. When SEP concentra-
tions can be measured, however, reported mean
concentrations range from 32 mU/mi [21] to 320
mU/mi [11]. Using a plasma concentration tech-
nique and the polycythemic mouse assay, Caro et al
recently found the normal plasma erythropoietin
concentration to be 7.8 mU/mi [22]. Even in the
more sensitive radioimmunoassay, the reported
normal values range from 3.7 to 11 mU/ml [20], to
52 to 84 mU/mi [23].
Using the fetal mouse liver cell assay, Napier et
al found a normal mean value of 150 mU/mi [24],
and De Klerk et al found a mean value of 48 mU/ml
for males and 29 mU/ml for females [25]. Therefore,
the mean SEP concentration of 136 mU/mi found in
our normal controls is in accordance with the re-
sults of Napier et al [24], but it is higher than the
values reported by De Klerk et al [25], who used the
40
5000
4000
3000
35
a,
2000
1I
I
1000
3000
2000
1000
C0
C,
500
C,C00
C
a,0
0
200
>.
a,
E
0U,
100
P <0.001 P <0.001
50
Before After Before After
Fig. 1. Serum erythropoietin concentrations (left panel, logarith-
mic scale) and hematocrits (right panel, linear scale) before and3
to 27 months after the start of regular hemodia!ysis treatment.
The thick line denotes the mean values.
a,30
C
25
C,20 o
Sa,I
15
Renal anemia and erythropoietin 385
same method as Napier et al used. The value we
found is also higher than that found by Lange and
Ichiki (mean of 37 mU/mi) who used the hemagglu-
tination-inhibition test [261, and higher than that
found by Lertora et a! (52 to 84 mU/mi) who used a
radioimmunoassay [231.
From this discrepancy in the absolute values
for normal SEP concentrations, two questions arise.
The first is related to the specifity of the method.
Hemopoietic tissue cultures have been shown to be
responsive to erythropoietin by Krantz, Gallien-
Lartigue, and Goidwasser [27], Cole and Paul [281,
Stephenson and Axelrad [29], Wardle et al [13], and
Dunn, Jarvis, and Greenman [14]. More recently,
Napier et a! showed that the fetal mouse liver cell
bioassay provides a quantitative measurement of
erythropoiesis stimulating activity in a variety of
hematologic disturbances, where the erythropoietic
activity ranged from 6000 to a few milliunits per mil-
liliter, and was significantly inversely correlated to
the corresponding hemoglobin concentrations. They
also reported that the erythropoietin in the human
serum could be completely blocked by anti-
erythropoietin antibodies [24]. This finding, which
was also reported by De Klerk et al [25], is in ac-
cordance with our data in Fig. 2.
Dukes et al [30] and Goldwasser, Eliason, and
Sikkema [31] showed that the polycythemic mouse
assay is not sensitive to desialated erythropoietin,
in contrast to cultures of hemopoietic cells, result-
ing in discrepancies of the measured erythropoietin
content when different samples with varying por-
tions of desialated erythropoietin were assayed. In
vitro assays, where the target organ alone (that is,
the hemopoietic cells) is directly exposed to the
erythropoietin, seem to be more specific than are in
vivo bioassays, where the sample has to be appli-
cated to specially prepared animals. More data,
however, will be necessary to confirm the specifici-
ty of the immunologic and biologic assays. Like
most investigators, we wish to use the name
"erythropoietin" operationally as a convenient and
well-known term, for erythropoietin preparations
are not yet proven to be chemically homogenous
[32].
The second question concerns the accuracy of
the measurement. The large differences of normal
control values might be attributed, at least in part,
to difficulties in calibrating the laboratory standard
against the international reference preparation. Be-
cause of the limited supply of the international ref-
erence material, calibration can be performed only
once or twice, and every accidental disturbance of
the measurement leads to an erroneous result,
which cannot be corrected by a larger number of
measurements. Even in the most experienced labo-
ratories, when the second International Reference
Preparation was calibrated against the first, results
of measurements of 10 U of erythropoietin by defi-
nition ranged from 5.4 to 19.1 U [17].
Fortunately, comparative studies are relatively
independent of the absolute levels of normal con-
trol values, as long as the data can be referred to
a sufficient number of normal control sera samples
measured under the same conditions.
Concentrations of SEP in patients with uremia are
usually not detectable or equal to those of normal
subjects when the polycythemic mouse assay is ap-
plied [9-11]. With immunologic methods, however,
concentrations in anemic patients with uremia
turn out to be higher than they are in normal per-
sons. Lertora et a!, using the radioimmunoassay,
found SEP concentrations in the range of 200 mU/mi
in patients with uremia, compared with 52 to 84
mU/mi in normal controls [23]. With a plasma con-
centration technique, Caro et al found erythro-
poietin concentrations of 3.4 to 53.1 mU/mI in neph-
nc and 2.8 to 5.5 mU/mi in anephric patients [22].
Interestingly, Lange and Ichiki found SEP concentra-
tions in 10 patients with uremia that ranged from 50
to 700 mU/mi when the hemaggiutination-inhibi-
tion-assay was used. Of these 10 sera samples, the
SEP concentrations in 9 were significantly lower
when the polycythemic mouse assay was applied.
The authors claim that serum samples from patients
with uremia are obviously underestimated in the
polycythemic mouse assay [261. Because the vol-
ume of the test serum sample applicated to the as-
say animal is usually 1 ml, which is in the range of
50% of the total blood volume and approximately
20% of the extraceilular volume of the test animal, a
bone-marrow depressing effect of the uremic serum
cannot be excluded.
The very high SEP concentrations found in our se-
verely uremic patients before the start of regular he-
modialysis treatment must be interpreted as a regu-
latory response to the extremely severe tissue hy-
poxia, resulting from the pronounced anemia as
well as from fluid overload with respiratory and car-
diac insufficiency of these decompensating patients.
Erythopoietin concentrations of patients in the ter-
minal phase of renal failure immediately before the
onset of dialysis treatment have not been studied
systematically by other investigators. There are,
however, sporadic data demonstrating that an ex-
treme hypoxic stimulus may cause a significant in-
crease of erythropoietin production even in end-
stage renal failure [8, 21, 33]. Fisher et a! reported
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two patients, one anephric and the other without
detectable excretory renal function, who exhibited
SEP concentrations of approximately 420 mU/ml fol-
lowing a hemolytic episode resulting from a copper
intoxication [33]. The extraordinary high 5EP con-
centrations have to be related to the pronounced
hypoxic state of the patients because in every pa-
tient SEP concentration dropped significantly to val-
ues slightly higher than those of normal subjects
when regular hemodialysis treatment had been car-
ried out for at least 3 months, and anemia, as well
as the clinical situation, including respiratory and
cardiac function, had improved. The mean SEP con-
centration of 182 mU/mi at that time compares very
well with the mean of 130 mU/mi measured in 88
nonnephrectomized patients who had been on regu-
lar hemodialysis treatment for more than 6 months
[34], and with that of 104 mU/mi found in 13 anephnc
hemodialysis patients on testosterone therapy [161.
In both groups of patients, we also used the fetal
mouse liver cell assay. In all three groups of dialysis
patients, mean hematocrit did not exceed 30%
(volume/volume). Thus, under a less severe hypoxic
stimulus, the measured SEP concentrations, which
were in the same range as those of normal controls,
have to be considered as being relatively decreased
in regard to the degree of anemia. In patients with-
out renal disease and with a comparable degree of
anemia, SEP concentrations were found to be con-
siderably higher when the polycythemic mouse
assay [35] and the fetal mouse liver cell assay [241
were used.
The observation that an additional hypoxic influ-
ence enables the diseased kidney to increase com-
pensatorily its production of erythropoietin sug-
gests that even in patients with terminal renal fail-
ure the regulatory feedback between hypoxia and
SEP concentration is sustained, probably operating
at a lower level. The decrease, however, of 5EP con-
centration following the onset of dialysis treatment,
in addition to the improvement of tissue oxygen-
ation, may have been caused, at least in part, by a
further reduction of renal mass with progress of re-
nal disease, which is most likely accompanied by a
further impairment of endocrine renal function. In
20 of our patients, in whom creatinine clearances
were measured together with SEP concentrations, it
declined from a mean of 5.7 to 1.4 mi/min/l.73 m2 (P
<0.001), indicating further loss of functioning renal
parenchyma.
On the basis of the present data, we conclude that
an increase of renal or extrarenal erythropoietin
production can be excluded as a cause of the rise of
peripheral hemoglobin concentrations following in-
troduction of maintenance hemodialysis treatment
in patients with end-stage renal failure, because in
all patients the hematocrits increased in spite of a
significant decrease of 5EP concentrations.
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